-
Presenter Profile: Advancing the Diabetic Eye Disease Care Continuum: Screening, Referral Pathways, Specialty Care, and Quality Outcomes
Caroline Presley, MD, MPH, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Friday, June 5, at 3:45 p.m. CT.
-
Presenter Profile: Lipoproteins and Insulin Sensitivity: Focus on ApoB and Lp(a)
Gissette Reyes-Soffer, MD, FAHA, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Saturday, June 6, at 8:00 a.m. CT.
-
Presenter Profile: Targeting the Source: Aldosterone Synthase Inhibitors in Diabetic Kidney Disease
Peter Rossing, MD, DMSc, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Saturday, June 6, at 8:00 a.m. CT.
-
Presenter Profile: How Low to Go? And in Whom? New Blood Pressure Targets in Diabetes
Daniel W. Jones, MD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Sunday, June 7, at 8:00 a.m. CT.
-
Presenter Profile: Pharmacotherapy Considerations
Elena Toschi, MD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Friday, June 5, at 3:45 p.m. CT.
-
Presenter Profile: Leveraging Artificial Intelligence for Precision Medicine in Youth-Onset Type 2 Diabetes
Mustafa Tosur, MD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Sunday, June 7, at 8:00 a.m. CT.
-
Presenter Profile: Next-Generation Pharmacotherapies to Reduce Hypoglycemia
Matthew J. Webber, PhD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Sunday, June 7, at 1:30 p.m. CT.
-
Presenter Profile: Understanding Diabetes Heterogeneity via Mining Multimodality Interconnected Data
Carl Yang, PhD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Sunday, June 7, at 8:00 a.m. CT.
-
Investigators to bring data on glucose management with oral orforglipron
Julio Rosenstock, MD, Francesco Giorgino, MD, PhD, and other panelists will discuss results from the ACHIEVE clinical trials, including ACHIEVE-3, which compared oral semaglutide and orforglipron for use in type 2 diabetes.
-
Researchers to share VESPER phase 2 clinical trial data
Investigators, including John B. Buse, MD, PhD, will discuss new insights from the VESPER program examining berobenatide, an ultra-long-acting glucagon-like peptide-1 (GLP-1) receptor agonist for weight management.